good to see the advisory board recommend approval by the FDA. We've needed an alternative to Mrna. It's been quite a rollercoaster with NVAX. Lot of shorts, expect some shenanigans along the way. Would think the guidance of 4-5B in revenues for 2022 looks good. Low P/E and small float could lead to some fireworks. Wouldn't be surprised to see a buyout.